WGS · XBRL financial data

GeneDx Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (WGS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	179	212	235	203	305	428
Cost of goods and services sold	175	229	261	113	111	129
Gross profit	4	(17)	(27)	90	194	298
Research and development	73	105	86	58	46	72
General and administrative	101	206	203	134	101	151
Other operating income (expense)	—	—	(6)	(7)	(3)	0
Operating income (loss)	(242)	(446)	(668)	(181)	(23)	(13)
Interest income	1	0	3	—	—	—
Interest expense	2	3	3	—	—	—
Other income (expense)	3	5	0	2	(13)	(4)
Income tax expense (benefit)	0	0	(49)	(1)	(0)	(0)
Net income (loss)	(241)	(245)	(549)	(176)	(52)	(21)
Earnings per share, basic‡ USD per share	(1,567,866.67)	(75.67)	(54.33)	(7.23)	(1.94)	(0.73)
Earnings per share, diluted‡ USD per share	(1,567,866.67)	(75.67)	(54.33)	(7.23)	(1.94)	(0.73)
Weighted average shares, basic‡ millions of shares	0	3	10	24	27	29
Weighted average shares, diluted‡ millions of shares	0	3	10	24	27	29

‡ Per-share figures and share counts are adjusted for the 1-for-33.333333333333336 stock split (December 2023); filings made before it reported them unadjusted.

Fiscal years (WGS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1	401	124	100	85	105
Marketable securities	—	—	0	30	56	66
Accounts receivable	32	27	43	—	38	74
Inventory	25	33	14	9	11	14
Prepaid and other current assets	—	—	32	11	9	9
Total current assets	1	484	213	182	198	268
Property and equipment, net	63	63	52	32	33	46
Right-of-use asset	—	0	33	27	26	23
Goodwill	0	0	—	—	0	14
Total assets	444	554	491	419	419	524
Accounts payable	27	45	46	10	8	2
Accrued liabilities	12	20	39	12	12	45
Current portion of long-term debt	2	0	5	0	1	5
Total current liabilities	0	101	144	59	55	109
Long-term debt	19	11	6	53	52	48
Lease liability, non-current	—	—	44	44	43	39
Total liabilities	86	166	237	191	174	216
Accumulated deficit	(40)	(575)	(1,124)	(1,300)	(1,352)	(1,373)
Total stockholders' equity	5	388	254	228	245	308
Total liabilities and equity	444	554	491	419	419	524
Common shares outstanding (cover page)‡ millions of shares	—	7	24	26	28	29

‡ Per-share figures and share counts are adjusted for the 1-for-33.333333333333336 stock split (December 2023); filings made before it reported them unadjusted.

Fiscal years (WGS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(241)	(245)	(549)	(176)	(52)	(21)
Stock-based compensation	120	219	42	(0)	9	32
Depreciation and amortization	12	22	59	20	8	10
Net cash from operating activities	(93)	(190)	(319)	(180)	(28)	33
Purchases of property and equipment	24	9	7	5	5	19
Net cash from investing activities	(32)	(21)	(141)	(44)	(30)	(62)
Proceeds from issuing common stock	0	350	198	—	—	—
Proceeds from long-term debt	16	0	0	49	0	0
Net cash from financing activities	129	494	197	186	44	48
Net change in cash	4	283	(263)	(38)	(14)	20

SIC 8000 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8000 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
GeneDx Holdings	60	114	(29)*	29.8M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Privia Health Group	412	not reported	1.1*	127.7M	—	Q2 FY26 10-QJun 30, 2026
Omada Health	222	88	4*	61.2M	—	Q2 FY26 10-QJun 30, 2026
Pennant Group	15	298	22*	34.9M	—	Q2 FY26 10-QJun 30, 2026
LifeStance Health Group	226	435	100*	382.1M	—	Q2 FY26 10-QJun 30, 2026
U S Physical Therapy	25	214	34*	14.9M	—	Q2 FY26 10-QJun 30, 2026
Talkspace	39	62	11*	165.8M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.